After thoughtful consideration, we have made the difficult decision to cancel this year’s Skyline Soirée.
This decision was not made lightly. As stewards of every donor dollar, we have a responsibility to ensure our fundraising events maximize the impact of every contribution. After carefully evaluating this year’s event, we determined that canceling Skyline Soirée was the most responsible decision to ensure we remain focused on advancing the American Cancer Society’s lifesaving mission.
If you purchased tickets or secured a sponsorship to Skyline Soirée, you’ll receive an email with details regarding your options from an ACS staff partner.
While we’re disappointed that we won’t gather under the Chicago skyline this year, our ABOA commitment to ending cancer remains stronger than ever and our work continues. Thank you for your continued partnership, compassion, and belief in our mission.
The Associate Board of Ambassadors (ABOA) is the American Cancer Society’s premier young professionals organization. The Chicago ABOA is made up of over 140 rising leaders from 100+ companies throughout Chicagoland. Since their inception in 2007, the Chicago ABOA has raised over $4.5 million to support the American Cancer Society.
ABOA members have the opportunity to network with others who are interested in making a difference in their community and significantly impacting the Society’s lifesaving mission.

SAVE LIVES
Your efforts will have a direct impact in saving the lives of cancer patients.

NETWORK
Meet fellow rising leaders who are committed to making a difference in their community.

GROW
Explore professional and personal development opportunities that will enhance your wellbeing.
For more than 10 decades, the American Cancer Society has been dedicated to pursuing better outcomes for every cancer, every life. Today, more people are surviving cancer than ever before, but there is still work to be done. Join us, support us, and help us end cancer as we know it, for everyone.
towards cancer research
winning scientists received research funding
through all patient support initiatives in 2024